BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 24056293)

  • 1. Antithrombin deficiency after prolonged asparaginase treatment in children with acute lymphoblastic leukemia.
    Ranta S; Heyman MM; Jahnukainen K; Taskinen M; Saarinen-Pihkala UM; Frisk T; Söderhäll S; Petrini P; Mäkipernaa AM
    Blood Coagul Fibrinolysis; 2013 Oct; 24(7):749-56. PubMed ID: 24056293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study.
    Mitchell LG; Andrew M; Hanna K; Abshire T; Halton J; Anderson R; Cherrick I; Desai S; Mahoney D; McCuster P; Wu J; Dahl G; Chait P; de Veber G; Lee KJ; Mikulis D; Ginsberg J; Way C;
    Cancer; 2003 Jan; 97(2):508-16. PubMed ID: 12518376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antithrombin supplementation III in childhood acute lymphoblastic leukemia treated with L-asparaginase.
    Matsuzaki A; Suminoe A; Hara T
    Pediatr Hematol Oncol; 2002 Dec; 19(8):601-3. PubMed ID: 12487838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study.
    Hunault-Berger M; Chevallier P; Delain M; Bulabois CE; Bologna S; Bernard M; Lafon I; Cornillon J; Maakaroun A; Tizon A; Padrazzi B; Ifrah N; Gruel Y;
    Haematologica; 2008 Oct; 93(10):1488-94. PubMed ID: 18728028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. L-Asparaginase lowers plasma antithrombin and mannan-binding-lectin levels: Impact on thrombotic and infectious events in children with acute lymphoblastic leukemia.
    Merlen C; Bonnefoy A; Wagner E; Dedeken L; Leclerc JM; Laverdière C; Rivard GE
    Pediatr Blood Cancer; 2015 Aug; 62(8):1381-7. PubMed ID: 25820776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the anticoagulant effect of a direct thrombin inhibitor and a low molecular weight heparin in an acquired antithrombin deficiency in children with acute lymphoblastic leukaemia treated with L-asparaginase: an in vitro study.
    Kuhle S; Lau A; Bajzar L; Vegh P; Halton J; Cherrick I; Anderson R; Desai S; McCusker P; Wu J; Abshire T; Mahoney D; Mitchell L
    Br J Haematol; 2006 Sep; 134(5):526-31. PubMed ID: 16856890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombosis associated with L-asparaginase therapy and low fibrinogen levels in adult acute lymphoblastic leukemia.
    Beinart G; Damon L
    Am J Hematol; 2004 Dec; 77(4):331-5. PubMed ID: 15551293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of low-molecular-weight heparin and antithrombin versus antithrombin alone for the prevention of symptomatic venous thromboembolism in children with acute lymphoblastic leukemia.
    Meister B; Kropshofer G; Klein-Franke A; Strasak AM; Hager J; Streif W
    Pediatr Blood Cancer; 2008 Feb; 50(2):298-303. PubMed ID: 17443678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coagulation and fibrinolysis in children with acute lymphoblastic leukaemia treated according to the COALL-05-92-protocol.
    Kirschke R; Nürnberger W; Eckhof-Donovan S; Nürnberger I; Göbel U
    Klin Padiatr; 1998; 210(4):285-90. PubMed ID: 9743967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study.
    Mitchell L; Andrew M; Hanna K; Abshire T; Halton J; Wu J; Anderson R; Cherrick I; Desai S; Mahoney D; McCusker P; Chait P; Abdolell M; de Veber G; Mikulis D
    Thromb Haemost; 2003 Aug; 90(2):235-44. PubMed ID: 12888870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of dose-reduced Medac L-asparaginase on coagulation in trial ALL-BFM 2000.
    Attarbaschi A; Mann G; Kronberger M; Witt V; Gadner H; Dworzak M
    Klin Padiatr; 2003; 215(6):321-6. PubMed ID: 14677096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Preliminary study on the safety and pharmacodynamic action of low dose L-asparaginase].
    Wu ZL; Chen FX; Ye TZ; Lai YH; Cui YQ; Zou YW; Lu CY; Lan SL; Zhong GY; Guan JM; Wei FG; Zhang H
    Zhonghua Xue Ye Xue Za Zhi; 2006 Jan; 27(1):14-6. PubMed ID: 16732932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Coagulation disorders during treatment with l-asparaginase preparations].
    Dobaczewski G
    Wiad Lek; 1998; 51 Suppl 4():227-32. PubMed ID: 10731973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia.
    Pession A; Valsecchi MG; Masera G; Kamps WA; Magyarosy E; Rizzari C; van Wering ER; Lo Nigro L; van der Does A; Locatelli F; Basso G; Aricò M
    J Clin Oncol; 2005 Oct; 23(28):7161-7. PubMed ID: 16192600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conservative treatment of L-asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia.
    Cohen H; Bielorai B; Harats D; Toren A; Pinhas-Hamiel O
    Pediatr Blood Cancer; 2010 May; 54(5):703-6. PubMed ID: 20063421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A regimen for antithrombin III substitution in patients with acute lymphoblastic leukemia under treatment with L-asparaginase.
    Mattioli Belmonte M; Gugliotta L; Delvos U; Catani L; Vianelli N; Cascione ML; Belardinelli AR; Mottola L; Tura S
    Haematologica; 1991; 76(3):209-14. PubMed ID: 1743591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antithrombin and fibrinogen levels as predictors for plasma L-asparaginase activity in children with acute lymphoblastic leukemia.
    Merlen C; Bonnefoy A; Afeich C; Théorêt Y; Laverdière C; Leclerc JM; Rivard GE
    Pediatr Blood Cancer; 2019 Jul; 66(7):e27729. PubMed ID: 30938058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. L-Asparaginase and the effect of age on coagulation and fibrinolysis in childhood acute lymphoblastic leukemia.
    Appel IM; Hop WC; van Kessel-Bakvis C; Stigter R; Pieters R
    Thromb Haemost; 2008 Aug; 100(2):330-7. PubMed ID: 18690355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebral venous thrombosis in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma during induction chemotherapy with l-asparaginase: The GRAALL experience.
    Couturier MA; Huguet F; Chevallier P; Suarez F; Thomas X; Escoffre-Barbe M; Cacheux V; Pignon JM; Bonmati C; Sanhes L; Bories P; Daguindau E; Dorvaux V; Reman O; Frayfer J; Orvain C; Lhéritier V; Ifrah N; Dombret H; Hunault-Berger M; Tanguy-Schmidt A
    Am J Hematol; 2015 Nov; 90(11):986-91. PubMed ID: 26214580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of glucocorticoids, E. coli- and Erwinia L-asparaginase on hemostatic proteins in children with acute lymphoblastic leukemia.
    Mall V; Thomas KB; Sauter S; Niemeyer CM; Sutor AH
    Klin Padiatr; 1999; 211(4):205-10. PubMed ID: 10472551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.